Complementary to these results, a study demonstrated that in colon cancer cells celecoxib inhibited the c-Met/AKT pathway, resulting in decreased phosphorylation and thus increased activity of GSK3β, leading to an increase in β-catenin phosphorylation [83]. Here, GSK3B is linked to malignant colon neoplasm.